RESEARCH AREA

Multiple Sclerosis

In the past few decades the MS field has witnessed a rapid expansion of new therapies. CNO has been involved for the past 25 years in the development of most of the new therapies for MS. CNO continues to contribute to the field and remains at the forefront of MS clinical research.

RESEARCH AREA

MS

There are currently several studies for Multiple Sclerosis taking place at the clinic. Please contact the coordinators of these studies, Victorine Sikati Foko or Chantal Paquette for more information.

Clinical Trials Active

These clinical trials are currently open and accepting participants. For more information contact information is listed below

These studies are underway, they/we are no longer enrolling new participants.

These clinical trials have concluded.

EFC17504 FREVIVA (Sanofi- Aventis)

Secondary progressive MS population
For more information contact Chantal Paquette at chantal.paquette@neuro-outaouais.ca

EFC17919 FREXALT (Sanofi-Aventis)

Relapsing remitting MS population
For more information contact Chantal Paquette at chantal.paquette@neuro-outaouais.ca

rTMS in\n Multiple Sclerosis

Non Invasive Neuromodulation in MS induced Spastic Paraparesis (the Villeneuve study)
For more information contact Chantal Paquette at chantal.paquette@neuro-outaouais.ca

Clinical Trial Presently Ongoing

MN43964 OLERO (Hoffman-LaRoche)

Chantal Paquette Recruitment is closed

GN41791 FENtrepide (Hoffmann-La Roche)

Victorine Sikati Foko Recruitment is closed

LTS17043 (Sanofi-Aventis)

Chantal Paquette Recruitment is closed

PASS OBS13434 (Genzyme - Sanofi)

Victorine Sikati Foko Recruitment is closed

LTS17261 (Sanofi-Aventis)

Victorine Sikati Foko Recruitment is closed

Publications:

View Publication

Multiple Sclerosis

Multiple Sclerosis (MS) affects more than 70,000 people in Canada. It is recognized as the most common cause of neurological disability in young adults in North America.

Greatest cause of neurological disability in young adults in North America. Autoimmune disease; genetically predisposed individuals to an environmental trigger

Participate

Multiple Sclerosis

MS typically begins in the second or third decade of life but can be diagnosed as early as age 10 and as late as in the 60s. It is a chronic, inflammatory, demyelinating, and neurodegenerative disease of the central nervous system (CNS), believed to result from a genetic predisposition combined with an environmental trigger. The disease course is heterogeneous, with 85% of patients starting with a relapsing-remitting course, which, after 15 to 20 years evolves into a secondary progressive course. The remaining 15% of patients will have a chronic, primary progressive course from the onset.

Common presenting symptoms include visual loss, sensory loss in one or both lower extremities, weakness of a limb or loss of balance, walking difficulties.

Clinical Evaluation

At CNO, we have a bilingual, multidisciplinary team consisting of neurologists, physiotherapists, medical assistants, specialized nurses and office administrators. Our team is experienced in the diagnosis, treatment and follow-up of patients with MS. Investigations and monitoring evaluations often include MRI, evoked potentials, blood tests and cerebrospinal fluid (CSF) analysis which can all be done at or arranged through the clinic. Initial consultations are available by referral from a physician.

Treatments

The treatment armamentarium used in MS has grown exponentially over the past few decades and continues to grow. To support physicians, CNO developed a repository of up-to-date information on the various MS treatments.
 
Many treatments in MS are administered intravenously. These can be received at CNO’s infusion clinic, administered by specialized MS nurses under the supervision of experienced neurologists.
 
While treatments in MS have changed the clinical evolution of the disease, they are not a cure. Much remains to be accomplished to fully understand the mechanisms of the disease, how to stop the progression of neurological disability and enable repair within the central nervous system (CNS).
 
CNO continues to be active in the field of clinical research in MS. Clinical trials at CNO are seen as a viable treatment option for patients whose disease does not respond optimally to currently available treatments.

rTMS in MS

Repetitive transcranial magnetic stimulation (rTMS) is a form of non-invasive neuromodulation. It is a method by which we can modulate how neuronal networks communicate within and across neuronal networks. It consists of inducing brief, repetitive, focal, small electrical currents in the brain using an electromagnet. It is commonly used to treat medication resistant depression. While it is still regarded as experimental, our experience with rTMS has convinced us that it can help alleviate a number of MS related symptoms such as weakness, spasticity, pain and neurogenic bladder. We are currently involved in clinical trials looking at rTMS in patients with MS.

Rehabilitation

Exercise is important for patients with multiple sclerosis (MS) to optimize mobility, support recovery from relapses, reduce pain and spasticity, and improve balance. However, exercise is often not a realistic option for individuals with MS without the help of experts and access to specialized equipment.
 
Through its partnership with Clinique NeuroGym, CNO offers patients with MS the opportunity to access physiotherapy services within the clinic. Clinique NeuroGym specializes in motor-enabling rehabilitation for individuals with a range of neurological conditions, including MS.
 
Together, CNO and Clinique Neurogym have conducted research projects in the field of MS rehabilitation and continue to collaborate to improve clinical outcomes of patients with MS.

Clinical Trials

Recruiting

Study: FREVIVA (EFC17504 )

Target population: secondary progressive MS population aged 18-60 For more information contact Chantal Paquette at chantal.paquette@neuro-outaouais.ca

Study: FREXALT (EFC17919 )

Target population: relapsing remitting MS population aged 18-55 For more information contact Chantal Paquette at chantal.paquette@neuro-outaouais.ca

Study: Non Invasive Neuromodulation in MS induced Spastic Paraparesis (CEV study)

Target population: MS induced walking impairment population aged 18-70
For more information contact Ibrahim Sangare at ibrahim.sangare@neuro-outaouais.ca

Ongoing

Study: OLERO (MN43964)

Chantal Paquette Recruitment is closed

Study: FENtrepide (GN41791)

Victorine Sikati Foko Recruitment is closed

Study: LTS17043

Chantal Paquette Recruitment is closed

Study: PASS OBS13434

Victorine Sikati Foko Recruitment is closed

Study: LTS17261

Victorine Sikati Foko Recruitment is closed

Completed

2022: ACT16753 study (Phase II)
2017: ENSEMBLE study (Phase III)
2021: ACT16877 study (Phase II)
2017: ASCLEPIOS study (Phase III)
2021: LIBERTO study (Phase IIIb/IV)
2020: GN41971 study (Phase III)
2020: HERCULES study (Phase III)
2019: ALITHIOS study (Phase IIIb)
2019: DRI BTK study (Phase II)
2019: NOVA study (Phase III)
2018: AFFINITY study (Phase II)
2016: EVOLVE study (Phase III)
2016: CHORDS study (Phase IIIb)
2015: TOPAZ study (Phase IIIb)
2014: INFORMS extension study (Phase III)
2013: SYNERGY study (Phase II)
2013: REsuMeS study (Phase II)
2012: MOBILE study (Phase II)
2011: OPERA study (Phase III)
2011: ASCEND study (Phase III)
2011: DreaMS extension study (Phase II)
2011: TERACLES study (Phase III)
2011: CARE-MS extension (Phase III)
2011: INFORMS study (Phase III)
2010: DECIDE study (Phase III)
2010: SURPASS study (Phase III)
2010: CBAF312A2201 ext. study (Phase II)
2010: DreaMS study (Phase II)
2009: LTS6050 study (Phase III)
2009: CBAF312A2201 study (Phase II)
2009: TOWER study (Phase III)
2009: LTS6047 study (Phase II)
2009: C32322 study (Phase II)
2009: CARE-MS-I study (Phase III)
2009: CARE-MS-II study (Phase III)
2008: PDY6045 study (Phase II)
2007: STRATA extension study (Phase III)
2007: TIME study (Phase II)
2007: BEYOND follow-up study (Phase IIIb)
2007: DEFINE study (Phase III)
2007: CLARITY extension study (Phase III)
2007: EFC6049 study (Phase III)
2007: EFC6049 study (Phase III)
2006: STRATA study (Phase III)
2005: OLYMPUS study (Phase II-III)
2005: HERMES study (Phase II)
2005: CHOICE study (Phase II)
2005: CLARITY study (Phase III)
2004: AFFIRM study extension (Phase III)
2004: BEYOND study (Phase IIIb)
2003: GLANCE study (Phase II)
2002: AFFIRM study (Phase III)

MS Related Publications